Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shifting Fortunes

This article was originally published in Start Up

Executive Summary

It appears that UK VC firm Merlin Ventures isn't going to merge with the Rothschild Bioscience Unit (RBU) after all. One key reason for calling the wedding off: With the Biotech resurgence, the value of International Biotechnology Trust (a quoted fund managed by RBU) has grown to $300 million, from $50-60 million last year. The shift in fortunes gives RBU more options--options likely to carry it away from Merlin.
Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090218

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel